Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer reports superiority of rivaroxaban to enoxaparin in thromboembolism prevention

Bayer reports superiority of rivaroxaban to enoxaparin in thromboembolism prevention

2nd June 2008

Bayer reports superiority of rivaroxaban to enoxaparin in thromboembolism prevention

Bayer has announced that that its once-daily rivaroxaban tablet has shown superiority to twice-daily injectable enoxaparin in the prevention of venous blood clots in patients who have undergone total knee replacement surgery.

The company said that the phase III trial showed rivaroxaban to be the first orally-administered anticoagulant to show superior efficacy when compared to the twice-daily injection of enoxaparin while maintaining low incidents of major bleeding rates.

At the European Federation of National Associations of Orthopaedics & Traumatology, it said the Record4 trial confirmed the earlier results of the Record1, 2 and 3 studies and added that it would make a submission for the compound to the relevant regulatory bodies during 2008.

AGG Turpie, professor of medicine at McMaster University, Canada, said: “The success of this trial strengthens my belief that direct Factor Xa inhibition with rivaroxaban has the potential to revolutionise the way we prevent the formation of dangerous blood clots.”

Bayer said that it is pleased the compound again exceeded its expectations adding that the study is a testament to the consistent strong results across the whole Record programme.

In July 2007, Bayer told the International Society on Thrombosis and Haemostasis that knee replacement patients receiving (Xarelto) rivaroxaban had a 49 per cent relative risk reduction in the risk of deep vein thrombosis, non-fatal pulmonary embolism and all-cause mortality compared to those receiving enoxaparin.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.